Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reports a single case of lichenoid cutaneous sarcoidosis that was unresponsive to standard treatments but showed marked improvement with the administration of oral tranilast.

This review examines the advances in nanostructured lipid carriers for treating hyperpigmentation but presents no new clinical results; the authors highlight their potential benefits and applications.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.

This review discusses the potential uses, benefits, and challenges of solid lipid nanoparticles in drug delivery systems but presents no new experimental findings.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study engineered a bioluminescent yeast strain responsive to androgenic chemicals, demonstrating rapid and sensitive detection suitable for high-throughput screening and environmental monitoring.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.

This article suggests that testosterone therapy might be considered if other treatments fail, but emphasizes discussing potential risks and benefits with patients before prescribing.

This study reports that metreleptin treatment in a boy with congenital generalized lipodystrophy significantly improved metabolic complications and overall health outcomes during the first year of therapy.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.

This study found that the nanostructured lipid carrier formulation with a 70:30 solid to liquid lipid ratio significantly increased the dissolution rate, entrapment efficiency, and stability of spironolactone compared to its raw form.

This study introduces a new device for measuring changes in hair stiffness and lubricity, which can help predict the effects of various hair treatments.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This study found that N-acetyl-glucosamine-loaded nanostructured lipid carriers showed promise for skin lightening in healthy volunteers by reducing melanin distribution.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

This study found that adding pioglitazone to either spironolactone or metformin improved metabolic parameters and insulin resistance in women with PCOS, despite an increase in BMI.